powered by     
 

About BIOAXXESS®

Established in 2003, BIOAXXESS started as a UK technology and business consultancy for innovative research biochemicals and diagnostics kits.

We were involved in the worldwide launch and product development of PEVIVA’s M30 Apoptosense ELISA -then distributed by ALEXIS Biochemicals, Switzerland back in 2000. Since 2011 we act as PEVIVA’s (now VLVbio’s) apoptosis biomarker assay expert and distributor in the UK and the Republic of Ireland.

We initiated and coached M30 Apoptosense ELISA novel diagnostic applications beyond the anti-cancer drug research and development. Well-documented applications now include chronic liver diseases (NASH, HBV and HCV) and today’s use as a “Liver MOT” in diagnostic routine laboratories in Germany dating back to 2009.

With the total cell death biomarker assay M65 ELISA this has been expanded to acute-on-chronic-liver failure (AOCLF) and Acute Liver Failure (ALF)/ Drug-induced Liver Injury (DILI) as well as Graft-versus-Host Disease (GVHD), organ transplantation and sepsis.

Through our long-standing unique assay insight and close collaboration with key opinion leaders, BIOAXXESS becomes your partner of choice for your biomarker project. We serve customers in >50 UK hospitals and universities, but also R&D in pharma and biotech and through CROs for drug safety and mechanistic biomarker analysis in clinical trials.

 

More about PEVIVA

PEVIVA's first-in-class CE-certified IVD cell death biomarker assays

M30-Apoptosense ELISA® (apoptotic Cytokeratin-18, ccK18, CK18 fragment)

M65® ELISA and the recently launched novel broad measuring range version 

M65 EpiDeath® ELISA (both detect total cell death: Cytokeratin-18)

have been independently validated by pharmaceutical companies and clinical research centres for diagnostic use in oncology and hepatology.

In Germany CK18F /M30 is recognized as a useful serum biomarker to detect apoptotic (cryptic) liver injury, prominent in non-alcoholic hepatosteatosis (NASH), the severe manifestation of non-alcoholic fatty liver disease (NAFLD) especially in obese individuals linked to metabolic syndrome and diabetes.

M30-Apoptosense ELISA® is reimbursed by Health Care Insurers in Germany and recommended by the Government Health Authority, especially in children and adolescents, who are overweight or obese and therefore at higher risk for developing NASH, which can progress to liver cancer or end-stage liver disease, cirrhosis.

PEVIVA's quality assurance system is certified according to SS-EN ISO 9001 and SS-EN ISO 13485.

 
Find out more

Clinicians and diagnostic laboratories in the UK interested in the determination of M30/CK18 at a BIOAXXESS® certified diagnostic partner laboratory on a fee-for-service basis, are invited to contact info@bioaxxess.co.uk.